Pacer Advisors
CTMX icon

Pacer Advisors’s CytomX Therapeutics CTMX Stock Holding History

Pacer Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,806
Closed -$29K – 1443
2021
Q1 		$29K Buy
3,806
+1,000
+36% +$7.92K ﹤0.01% 1481
2020
Q4 		$18K Buy
2,806
+366
+15% +$2.62K ﹤0.01% 1487
2020
Q3 		$16K Buy
+2,440
New +$18.1K ﹤0.01% 1362
2018
Q4 		– Sell
-4,431
Closed -$82K – 659
2018
Q3 		$82K Buy
+4,431
New +$101K ﹤0.01% 1111
2018
Q1 		– Sell
-525
Closed -$11K – 1057
2017
Q4 		$11K Buy
+525
New +$10.9K ﹤0.01% 1138

Other funds holding CTMX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Pacer Advisors's CTMX Position: Q2 2021 in Review

Pacer Advisors sold out of CytomX Therapeutics (CTMX) in Q2 2021, closing a stake of 3,806 shares — an estimated $29K sold.

Pacer Advisors first reported a position in CTMX in Q4 2017 and held it in 5 quarters. The position peaked at $82K in Q3 2018. 122 funds tracked by Wall St. Rank hold CTMX as of Q2 2021.

  • Pacer Advisors reported no remaining CytomX Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Pacer Advisors sold 3,806 CytomX Therapeutics shares in Q2 2021, an estimated $29K.
  • Pacer Advisors first reported a position in CytomX Therapeutics in Q4 2017 and held it in 5 quarters.
  • Pacer Advisors's CytomX Therapeutics position peaked at $82K in Q3 2018.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2021.

Based on Pacer Advisors's 13F filing for Q2 2021, filed 21 Jul 2021.